newsfilter
← Latest News
GlobeNewswire·

Turning Point Therapeutics Announces Achievement of Enrollment Goal for TRIDENT-1 NTRK-Positive TKI-Pretreated Advanced Solid Tumor Patients and Plans for Pre-NDA Meeting for This Patient Population

Enrollment target achieved for expansion cohort 6 (EXP-6) for repotrectinib in NTRK-positive TKI-pretreated advanced solid tumors Company anticipates second repotrectinib pre-NDA meeting in first quarter 2023 to discuss registration timeline for NTRK